Analyzing immune cells in children undergoing anesthesia
High Dimensional Analysis of Immune Cells Using scRNA-seq in Pediatric Patients With Allergic Reactions to Neuromuscular Blockers
This study looks at how immune cells in children aged 2 to 18 react to anesthesia and a specific medication to better understand their immune response and any potential allergies.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 294 (estimated) |
| Ages | 2 Years to 18 Years |
| Sex | All |
| Sponsor | Seoul National University Hospital Academic / other |
| Locations | 1 site (Seoul) |
| Trial ID | NCT05820802 on ClinicalTrials.gov |
What this trial studies
This observational study aims to characterize immune cells in pediatric patients aged 2 to 18 years who are undergoing general anesthesia and are expected to receive Rocuronium, a neuromuscular blocking agent. The study utilizes single-cell transcriptomic analysis to gain insights into the immune response during anesthesia, particularly in the context of potential drug allergies. By focusing on this specific patient population, the research seeks to enhance understanding of immune cell behavior in response to anesthesia and associated medications.
Who should consider this trial
Good fit: Ideal candidates are pediatric patients aged 2 to 18 years who are scheduled for surgery requiring general anesthesia with Rocuronium.
Not a fit: Patients with autoimmune diseases or those on immunomodulatory treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the safety and management of drug allergies in pediatric patients undergoing anesthesia.
How similar studies have performed: While there is ongoing research in immune cell analysis, this specific approach in pediatric patients undergoing anesthesia is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pediatric patients between the ages of 2 and 18 undergoing general anesthesia and surgery using the neuromuscular blocker, rocuronium. Exclusion Criteria: * Patients who have received immunomodulators, immunosuppressants, etc. * Patients with autoimmune diseases (rheumatoid arthritis, lupus, Behcet's disease, etc.) * Patients who regularly take, or have taken within 4 weeks, medications that may affect the immune system (oral steroids, anti-inflammatories, etc.) * Other cases where the Principal Investigator determines that it is difficult to conduct the study.
Where this trial is running
Seoul
- Seoul National University Hospital — Seoul, South Korea (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.